Oxaliplatin-d10 (Synonyms: Lipoxal-d10)

Oxaliplatin-d₁₀ is intended for use as an internal standard for the quantification of oxaliplatin by GC- or LC-MS. Oxaliplatin is a platinum-containing DNA-crosslinking agent.¹ It induces the formation of DNA inter- and intrastrand crosslinks and DNA-protein adducts, inhibits DNA and RNA synthesis, and induces apoptosis in cancer cells. Oxaliplatin is cytotoxic to cisplatin-sensitive A2780(1A9) and KB-3-1 cells and cisplatin-resistant A2780-E(80) and KB-CP20 cells (IC₅₀s = 0.12, 0.39, 4.7, and 2.7 µM, respectively).² It reduces tumor growth in an HCCLM3 mouse xenograft model when administered at doses of 5 or 10 mg/kg once per week.³ Formulations containing oxaliplatin have been used in the treatment of advanced colorectal cancer and as adjuvants in stage III colon cancer.

1.Alcindor, T., and Beauger, N.Oxaliplatin: A review in the era of molecularly targeted therapyCurr. Oncol.18(1)18-25(2011) 2.Rixe, O., Ortuzar, W., Alvarez, M., et al.Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute’s Anticancer Drug Screen panelBiochem. Pharmacol.52(12)1855-1865(1996) 3.Wang, Z., Zhou, J., Fan, J., et al.Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growthExpert Opin. Investig. Drugs18(11)1595-1604(2009)